naproxen has been researched along with 2019 Novel Coronavirus Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clark, S; Clees, WI; Elkin, KR; Elliott, HA; Hayden, KR; Jones, M; Mashtare, ML; Preisendanz, HE; Read, AF; Richard, TL; Shreve, MJ; Silverman, J; Veith, TL; Watson, JE | 1 |
| Abdool-Ghany, AA; Gidley, ML; Klaus, J; Sahwell, PJ; Sinigalliano, CD; Solo-Gabriele, HM | 1 |
| Asonye, C; Dwumfour, N; Karami, S; McCulley, L; Pinnow, E; Pratt, V; Zhou, EH | 1 |
| Apata, J; Mosholder, AD; Pennap, DD | 1 |
| Azadi, H; Darabi, E; Fathi, S; Ghanei, M; Ghazale, AH; Ghazvini, A; Izadi, M; Jafari, R; Movaseghi, F; Mozafari, A; Panahi, Y; Parsaei, MR; Ranjkesh, MH; Rezapour, M; Saadat, SH; Salesi, M; Vahedi, E; Zand, N | 1 |
| Dahl, TA; Iversen, JM; Kiani, P; McMann, L; Scholey, A; Verster, JC | 1 |
6 other study(ies) available for naproxen and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Impacts of the COVID-19 pandemic on pharmaceuticals in wastewater treated for beneficial reuse: Two case studies in central Pennsylvania.
Topics: Acetaminophen; Ampicillin; Animals; Anti-Bacterial Agents; COVID-19; Dexamethasone; Doxycycline; Environmental Monitoring; Humans; Hydroxychloroquine; Naproxen; Ofloxacin; Pandemics; Pennsylvania; Pharmaceutical Preparations; Soil; Sulfamethoxazole; Trimethoprim; Waste Disposal, Fluid; Wastewater; Wastewater-Based Epidemiological Monitoring; Water Pollutants, Chemical | 2022 |
Fecal indicator bacteria levels at a marine beach before, during, and after the COVID-19 shutdown period and associations with decomposing seaweed and human presence.
Topics: Acetaminophen; Animals; Bacteria; Bathing Beaches; Caffeine; COVID-19; Dogs; Enterococcus; Environmental Monitoring; Feces; Humans; Ibuprofen; Naproxen; Seaweed; Water; Water Microbiology | 2022 |
Trends in pediatric nonprescription analgesic/antipyretic exposures during the COVID-19 pandemic.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Antipyretics; Aspirin; Child; Child, Preschool; COVID-19; Female; Humans; Ibuprofen; Male; Naproxen; Nonprescription Drugs; Pandemics; Poison Control Centers; United States | 2023 |
The use of analgesics for intentional self-poisoning: Trends in U.S. poison center data.
Topics: Acetaminophen; Adolescent; Adult; Analgesics; Aspirin; Child; COVID-19; Female; Humans; Ibuprofen; Male; Naproxen; Pandemics; Poison Control Centers; Poisons; Young Adult | 2023 |
The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
Topics: Adult; Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Iran; Length of Stay; Levofloxacin; Lopinavir; Male; Meropenem; Middle Aged; Naproxen; Oseltamivir; Pneumonia, Viral; Prednisolone; Retrospective Studies; Ritonavir; Treatment Outcome; Vancomycin | 2020 |
In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytopathogenic Effect, Viral; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Humans; Indomethacin; Ketotifen; Naproxen; SARS-CoV-2 | 2021 |